Nurix Therapeutics, Inc. NRIX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.16M-70.9% | $247.93M+212% | $79.41M-6.8% | $85.16M+10.9% | $76.82M-30.7% | ||
| $554.39M-8.6% | $606.82M+37.7% | $440.6M-14.5% | $515.33M-8.6% | $563.7M-9.0% | ||
| $21.7M-3.5% | $22.49M+9.7% | $20.5M+9.2% | $18.77M+1.8% | $18.45M+3.9% | ||
| $636.13M-7.6% | $688.14M+31.7% | $522.47M-11.7% | $591.56M-3.8% | $615.04M-8.1% | ||
| $10.29M-8.2% | $11.22M+30.3% | $8.61M+44.6% | $5.95M-29.1% | $8.4M-26.9% | ||
| $18.75M+6.7% | $17.58M-32.4% | $25.99M-5.2% | $27.42M-10.4% | $30.59M-20.3% | ||
| $92.2M+6.6% | $86.47M+5.0% | $82.35M+8.9% | $75.61M-16.0% | $89.99M-6.1% | ||
| $155.24M+3.9% | $149.39M-0.6% | $150.22M+4.4% | $143.95M+7.3% | $134.13M-5.8% | ||
| 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | ||
| -$1.09B-8.7% | -$1B-8.5% | -$925.01M-10.3% | -$838.58M-5.5% | -$795.12M-7.6% | ||
| $480.89M-10.7% | $538.75M+44.7% | $372.25M-16.8% | $447.6M-6.9% | $480.92M-8.7% | ||
| $636.13M-7.6% | $688.14M+31.7% | $522.47M-11.7% | $591.56M-3.8% | $615.04M-8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Nurix Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 6.01 — current assets exceed current liabilities.
- Where does Nurix Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.